Design of molecular hybrids of phthalimide-triazole agents with potent selective MCF-7/HepG2 cytotoxicity: Synthesis, EGFR inhibitory effect, and metabolic stability

• Published in: Bioorganic chemistry Vol. 111; p. 104835
• Main Authors: Ihmaid, Saleh K., Alraqa, Shaya Yahya, Aouad, Mohamed R., Aljuhani, Ateyatallah, Elbadawy, Hossein M., Salama, Samir A., Rezki, Nadjet, Ahmed, Hany E.A.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-06-2021
• Subjects: 1,2,3-triazoles; Anticancer activity; Apoptosis study; EGFR kinases; Phthalimide analogues; Apoptosis study; Phthalimide analogues; EGFR kinases; 1,2,3-triazoles; Anticancer activity
• ISSN: 0045-2068; 1090-2120
• DOI: 10.1016/j.bioorg.2021.104835

[Display omitted]
•Novel synthesis of phthalimide-triazole hybrids of EGFR inhibitors.•Click synthesis of new anticancer-based 1,2,3 triazoles.•Compound 6f selectively inhibits the MCF-7 growth and has potent EGFR inhibitory activity.•Metabolic stability approach was underestimated and validated for the active compound.
This study reports an efficient and convenient click chemistry synthesis of a novel series of phthalimide scaffold linked to 1,2,3 triazole ring and terminal lipophilic fragments. Structures of newly synthesized compounds were well characterized by different spectroscopic tools. In vitro MTT cytotoxicity assay was performed comparing the cytotoxic effects of newly synthesized compounds to staurosporine using three different types: human liver cancer cell line (HepG2), Michigan cancer foundation-7 (MCF-7) and human colorectal carcinoma cell line (HCT116). The initial screening showed excellent to moderate anticancer activity for these newly synthesized compounds with high degree of cell line selectivity with micromolar (µM) half maximal inhibitory concentration (IC50) values against tumor cells. The SAR analysis of these derivatives confirmed the role of molecular fragments including phthalimide, linker, triazole, and terminal tails in correlation to activity. In addition, enzymatic inhibitory assay against wild type EGFR was performed for the most active compounds to get more details about their mechanism of action. In order to further explore their binding affinities, molecular docking simulation was studied against EGFR site. The results obtained from molecular docking study and those obtained from cytotoxic screening were correlated. One of the most prominent analogs is (6f) with terminal disubstituted ring and amide linker showed selective MCF-7 cytotoxicity profile with IC50 0.22 µM and 79 nM to EGFR target. Extensive structure activity relationship (SAR) analyses were also carried out. The pharmacokinetic profile of (6f) was studied showing good metabolic stability and long duration behavior. This design offered a potent selective anticancer phthalimide-triazole leads for further optimization in cancer drug discovery.